TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is a medical technology company that completed its de-SPAC transaction with MedTech Acquisition Corp, which traded under the ticker MTAC and was sponsored by MedTech Acquisition Partners, LLC. The blank-check vehicle, which went public in 2021, targeted the healthcare and medical technology sector. On October 19, 2023, TriSalus filed an amended S-1/A registration statement with the SEC, reflecting continued post-merger compliance activity as the combined company established its public reporting footing. TriSalus focuses on oncology drug delivery systems, specifically for liver and pancreatic cancer treatment. For full filing history, sponsor details, and deal analytics on MTAC and TriSalus Life Sciences, sign up for SpacDesk at spacdesk.com.